Bonesupport Holding

Declaration of Voting Results & Voting Rights Announcements • Sep 29, 2017

Change in number of shares and votes in BONESUPPORT HOLDINGAB (publ)

Lund, Sweden, 18:00 CEST 29th September 2017 - During September, the number of shares and votes in BONESUPPORTHOLDINGAB (publ) has increased due to the exercise of warrants. As of 29th September, 2017, the number of shares and votes in BONESUPPORTHOLDINGAB (publ) amounts to 49,650,651.

For more information contact:

Richard Davies, CEO

Tel: +46 (0) 46 286 53 71

Björn Westberg, CFO

Tel: +46 (0) 46 286 53 60

Email: ir@bonesupport.com

The information in the press release is such that BONESUPPORTHOLDINGAB (publ) is required to disclose pursuant to the Swedish Financial Instruments TradingAct. The information was submitted for publication, through the agency of the contact persons set out above, at 18:00 CETon September 29, 2017.

About BONESUPPORT™

BONESUPPORT™ is an innovative and rapidly growing commercial stage orthobiologics company, based in Lund, Sweden. The Company develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs directly into the bone void. BONESUPPORT's marketed bio-ceramic bone graft substitutes CERAMENT®BONE VOID FILLER(BVF), CERAMENT®G* and CERAMENT®V* are all based on the Company's novel and proprietary CERAMENTtechnology platform.

The Company's products are targeting a large addressable market opportunity across trauma, chronic osteomyelitis (bone infection), revision arthroplasty (replacement of a joint prosthesis) and infected diabetic foot.

BONESUPPORT's total sales increased from SEK 41 million in 2014 to SEK 105 million in 2016, representing a compound annual growth rate of 60 percent. The Company's financial target is to achieve revenue exceeding SEK 500 million in the financial year 2020, with a gross margin exceeding 85 percent and a positive operating profit.

The Company's research and development is focused on the continuing development and refinement of its CERAMENTtechnology to extend its use into additional indications by the elution of other drugs and therapeutic agents. The Company currently has a pipeline of pre-clinical product candidates that have been designed to promote bone growth.

BONESUPPORTis listed on Nasdaq Stockholm and trades under the ticker "BONEX" (ISINcode: SE0009858152). Further information is available at www.bonesupport.com

*CERAMENTG: Not available in the United States, for investigational use only. CERAMENTV: Not available in the United States.

BONESUPPORT™ and CERAMENT®are registered trademarks.